PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score
出版年份 2021 全文链接
标题
PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score
作者
关键词
-
出版物
Cancers
Volume 13, Issue 18, Pages 4659
出版商
MDPI AG
发表日期
2021-09-17
DOI
10.3390/cancers13184659
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants
- (2020) Valerie Pestinger et al. Molecular Diagnosis & Therapy
- Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
- (2020) Matthew Kyle Labriola et al. Journal for ImmunoTherapy of Cancer
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Evaluation of a Hybrid Capture–Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes
- (2020) Leonie I. Kroeze et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing
- (2020) Carina Heydt et al. Scientific Reports
- A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases
- (2020) Richard S. P. Huang et al. MODERN PATHOLOGY
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer
- (2019) Yanhui Chen et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
- (2019) Jiaxin Zhu et al. Frontiers in Pharmacology
- Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
- (2019) Andrea Forschner et al. Journal for ImmunoTherapy of Cancer
- Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
- (2019) Laura Fancello et al. Journal for ImmunoTherapy of Cancer
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2019) Angel Garcia-Diaz et al. Cell Reports
- Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
- (2018) E E Vokes et al. ANNALS OF ONCOLOGY
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention
- (2018) Maeve A Lowery et al. CLINICAL CANCER RESEARCH
- Accurate Pan-Cancer Molecular Diagnosis of Microsatellite Instability by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing
- (2018) Adam Waalkes et al. CLINICAL CHEMISTRY
- Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
- (2018) Mohamed E. Salem et al. MOLECULAR CANCER RESEARCH
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Size Matters: Dissecting Key Parameters for Panel-Based Tumor Mutational Burden (TMB) Analysis
- (2018) Ivo Buchhalter et al. INTERNATIONAL JOURNAL OF CANCER
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan
- (2018) Jason C. Hsu et al. PLoS One
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer
- (2018) Laura G. Baudrin et al. Frontiers in Oncology
- Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.
- (2017) Douglas Buckner Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
- (2017) Haipeng Xu et al. Scientific Reports
- Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma
- (2017) Yun Shin Chun et al. Cancer Control
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- GenVisR: Genomic Visualizations in R
- (2016) Zachary L. Skidmore et al. BIOINFORMATICS
- Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice
- (2016) Apurva Jain et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- Novel technologies and emerging biomarkers for personalized cancer immunotherapy
- (2016) Jianda Yuan et al. Journal for ImmunoTherapy of Cancer
- Epstein-Barr virus infection serves as an independent predictor of survival in patients with lymphoepithelioma-like gastric carcinoma
- (2015) Byung-Hoon Min et al. Gastric Cancer
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Performance comparison of four exome capture systems for deep sequencing
- (2014) Chandra Sekhar Chilamakuri et al. BMC GENOMICS
- Microsatellite Instability Detection by Next Generation Sequencing
- (2014) S. J. Salipante et al. CLINICAL CHEMISTRY
- Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
- (2014) Mahesh Yadav et al. NATURE
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Reflex Immunohistochemistry and Microsatellite Instability Testing of Colorectal Tumors for Lynch Syndrome Among US Cancer Programs and Follow-Up of Abnormal Results
- (2012) Laura C. Beamer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epitope Landscape in Breast and Colorectal Cancer
- (2008) N. H. Segal et al. CANCER RESEARCH
- Differences and evolution of the methods for the assessment of microsatellite instability
- (2008) L Laghi et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now